title: Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".
abstract: After more than 30 years, landmark progress has been made in the treatment of cancer, and melanoma in particular, with the success of new molecules such as ipilimumab, vemurafenib and active specific immunization.After the first congress in December 2010, the second edition of "Melanoma Research: a bridge from Naples to the World" meeting, organized by Paolo A. Ascierto (INT, Naples, Italy), Francesco M. Marincola (NIH, Bethesda, USA), and Nicola Mozzillo (INT, Naples, Italy) took place in Naples, on 5-6 December 2011. We have identified four new topics of discussion: Innovative Approaches in Prevention, Diagnosis and Surgical Treatment, New Pathways and Targets in Melanoma: An Update about Immunotherapy, and Combination Strategies. This international congress gathered more than 30 international faculty members and was focused on recent advances in melanoma molecular biology, immunology and therapy, and created an interactive atmosphere which stimulated discussion of new approaches and strategies in the field of melanoma.
authors.affiliation: Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy. paolo.ascierto@gmail.com
authors.forename: Paolo A
authors.initials: PA
authors.lastname: Ascierto
authors.forename: Antonio M
authors.initials: AM
authors.lastname: Grimaldi
authors.forename: Brendan
authors.initials: B
authors.lastname: Curti
authors.forename: Mark B
authors.initials: MB
authors.lastname: Faries
authors.forename: Soldano
authors.initials: S
authors.lastname: Ferrone
authors.forename: Keith
authors.initials: K
authors.lastname: Flaherty
authors.forename: Bernard A
authors.initials: BA
authors.lastname: Fox
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Gajewski
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Gershenwald
authors.forename: Helen
authors.initials: H
authors.lastname: Gogas
authors.forename: Kenneth
authors.initials: K
authors.lastname: Grossmann
authors.forename: Axel
authors.initials: A
authors.lastname: Hauschild
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
authors.forename: Richard
authors.initials: R
authors.lastname: Kefford
authors.forename: John M
authors.initials: JM
authors.lastname: Kirkwood
authors.forename: Sancy
authors.initials: S
authors.lastname: Leachmann
authors.forename: Michele
authors.initials: M
authors.lastname: Maio
authors.forename: Richard
authors.initials: R
authors.lastname: Marais
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Palmieri
authors.forename: Donald L
authors.initials: DL
authors.lastname: Morton
authors.forename: Antoni
authors.initials: A
authors.lastname: Ribas
authors.forename: David F
authors.initials: DF
authors.lastname: Stroncek
authors.forename: Rodney
authors.initials: R
authors.lastname: Stewart
authors.forename: Ena
authors.initials: E
authors.lastname: Wang
authors.forename: Nicola
authors.initials: N
authors.lastname: Mozzillo
authors.forename: Franco M
authors.initials: FM
authors.lastname: Marincola
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D035843:Biomedical Research; D006801:Humans; D007167:Immunotherapy; D007558:Italy; D008545:Melanoma / Q000276:immunology / Q000517:prevention & control / Q000601:surgery / Q000628:therapy*; D051379:Mice; D016032:Randomized Controlled Trials as Topic; D012878:Skin Neoplasms / Q000601:surgery / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents